Memphis Pharmaceuticals
Memphis Pharmaceuticals operates in various business sectors.
Market Cap & Net Worth: Memphis Pharmaceuticals (MPCI)
Memphis Pharmaceuticals (EGX:MPCI) has a market capitalization of $28.38K (EGP1.44 Million) as of March 18, 2026. Listed on the EGX stock exchange, this Egypt-based company holds position #43199 globally and #24 in its home market, demonstrating a -4.41% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Memphis Pharmaceuticals's stock price EGP155.10 by its total outstanding shares 9253 (9.25K).
Memphis Pharmaceuticals Market Cap History: 2015 to 2026
Memphis Pharmaceuticals's market capitalization history from 2015 to 2026. Data shows growth from $1.59K to $28.38K (31.87% CAGR).
Memphis Pharmaceuticals Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Memphis Pharmaceuticals's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of MPCI by Market Capitalization
Companies near Memphis Pharmaceuticals in the global market cap rankings as of March 18, 2026.
Key companies related to Memphis Pharmaceuticals by market ranking:
- MBEL (NSE:MBEL): Ranked #43190 globally with a market cap of $29.61K USD ( ₹2.56 Million INR).
- HT5 N LTD (SW:HT5): Ranked #43191 globally with a market cap of $29.60K USD ( CHF27.10K CHF).
- Infraware (KO:041020): Ranked #43200 globally with a market cap of $29.45K USD ( ₩43.13 Million KRW).
- ACTIA GROUP SA INH.EO-75 (F:AG9): Ranked #43201 globally with a market cap of $29.44K USD ( €28.68K EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #43190 | MBEL | NSE:MBEL | $29.61K | ₹280.75 |
| #43191 | HT5 N LTD | SW:HT5 | $29.60K | CHF3.00 |
| #43200 | Infraware | KO:041020 | $29.45K | ₩4545.00 |
| #43201 | ACTIA GROUP SA INH.EO-75 | F:AG9 | $29.44K | €2.95 |
Memphis Pharmaceuticals Historical Marketcap From 2015 to 2026
Between 2015 and today, Memphis Pharmaceuticals's market cap moved from $1.59K to $ 28.38K, with a yearly change of 31.87%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | EGP28.38K | -0.70% |
| 2025 | EGP28.59K | +199.58% |
| 2024 | EGP9.54K | -16.86% |
| 2023 | EGP11.48K | +252.30% |
| 2022 | EGP3.26K | -15.24% |
| 2021 | EGP3.84K | +9.95% |
| 2020 | EGP3.50K | +102.12% |
| 2019 | EGP1.73K | +8.62% |
| 2018 | EGP1.59K | -43.72% |
| 2017 | EGP2.83K | +45.82% |
| 2016 | EGP1.94K | +22.22% |
| 2015 | EGP1.59K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Memphis Pharmaceuticals was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $28.38K USD |
| MoneyControl | $28.38K USD |
| MarketWatch | $28.38K USD |
| marketcap.company | $28.38K USD |
| Reuters | $28.38K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.